LRMR
Larimar Therapeutics, Inc. · Healthcare · Market cap $326.2M
Insiders bought $402K net in the last 90 days ·0 sellers, 9 buyers· latest Form 4 filed Nov 18, 2026
Insider Buying
$26.1M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
10
in the rolling window
Latest filing
Nov 18, 2026
Clayton Russell
Larimar Therapeutics, Inc. (LRMR) has 19 SEC Form 4 filings (22 transaction rows) in the rolling window, disclosed by 10 distinct insiders. Most recent filing: Nov 18, 2026.
Inside the rolling window, 10 insiders at Larimar Therapeutics, Inc. reported 14 open-market purchases totaling $26.1M and no open-market sales. The most active filer is Director Hamilton Thomas Edward with 3 filings. Insiders have net bought $569K over the trailing 6 months. The most recent open-market filing is a purchase of 3,322 shares by Chief Medical Officer Clayton Russell, dated Nov 16, 2026, worth $10K.
- Industry:Biotechnology
- CEO:Carole S. Ben-Maimon
- Employees:71
- HQ:Bala Cynwyd, PA, US
- IPO:2014-06-19
| Source | |||||||
|---|---|---|---|---|---|---|---|
Clayton RussellFirst filing | Chief Medical Officer | Purchase | 3,322 | $10K | Nov 18 | -2.6% | SEC ↗ |
SHERMAN JEFFREY WFirst in 9 months | Director | Purchase | 3,289.474 | $10K | Nov 16 | cluster+4.7% | SEC ↗ |
Hamilton Thomas EdwardFirst in 4 months | Director | Purchase | 70,000 | $187K | Nov 13 | cluster+4.0% | SEC ↗ |
Celano MichaelFirst filing | Chief Financial Officer | Purchase | 18,460 | $50K | Nov 12 | cluster+16.3% | SEC ↗ |
Shankar GopiFirst filing | Chief Development Officer | Purchase | 5,000 | $14K | Nov 12 | cluster+16.3% | SEC ↗ |
Truitt JosephFirst filing | Director | Purchase | 3,500 | $10K | Nov 12 | +16.3% | SEC ↗ |
Harlow John B. Jr.First filing | President and COO | Purchase | 17,800 | $50K | Nov 12 | cluster+16.3% | SEC ↗ |
THOMAS FRANK EFirst in 9 months | Director | Purchase | 8,000 | $22K | Nov 12 | cluster+16.3% | SEC ↗ |
BEN-MAIMON CAROLEFirst filing | President and CEO | Purchase | 18,050 | $50K | Nov 12 | cluster+16.3% | SEC ↗ |
Hamilton Thomas EdwardFirst in 4 months | Director | Purchase | 50,000 | $167K | Jul 8 | -13.0% | SEC ↗ |
Flynn James EFirst in 3 months | * Director by Deputization | Purchase | 5,000,000 | $25.0M | Mar 2 | — | SEC ↗ |
THOMAS FRANK EFirst filing | Director | Purchase | 5,000 | $25K | Mar 2 | — | SEC ↗ |
SHERMAN JEFFREY WFirst filing | Director | Purchase | 5,000 | $25K | Mar 2 | — | SEC ↗ |
Hamilton Thomas EdwardFirst filing | Director | Purchase | 100,000 | $500K | Mar 2 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does LRMR have?
Larimar Therapeutics, Inc. (LRMR) has 19 SEC Form 4 filings (22 transaction rows) in the rolling 365-day window, disclosed by 10 distinct insiders. Most recent filing: Nov 18, 2026.
When was the most recent SEC Form 4 filing for LRMR?
The most recent Form 4 filing for LRMR on Tracefour is dated Nov 18, 2026.
Who is the most active insider at LRMR?
The most active SEC Form 4 filer at LRMR in the rolling window is Director Hamilton Thomas Edward, with 3 filings.
What is the net insider flow at LRMR over the last 6 months?
Over the trailing 180 days, insiders at LRMR have net bought $569K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at LRMR in the current window?
Inside the rolling window, insiders at LRMR bought $26.1M and sold $0 based on SEC Form 4 filings.
Can I get alerts for LRMR insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Larimar Therapeutics, Inc. (LRMR). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Larimar Therapeutics, Inc. is in the Healthcare sector.